Results 31 to 40 of about 287,802 (318)

Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera

Haematologica, 2011
TET2 mutations are found in polycythemia vera and it was initially reported that there is a greater TET2 mutational burden than JAK2V617F in polycythemia vera stem cells and that TET2 mutations precede JAK2V617F.
Sabina I. Swierczek, Donghoon Yoon, Christine Bellanné-Chantelot, Soo Jin Kim, Cécile Saint-Martin, Francois Delhommeau, Albert Najman, Josef T. Prchal   +7 more
doaj   +1 more source

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

Haematologica, 2008
We analyzed the effect of hydroxyurea on the JAK2V617F allelic ratio (%JAK2V617F), measured in purified blood granulocytes, of patients with polycythemia vera and essential thrombocythemia.
François Girodon, Céline Schaeffer, Cédric Cleyrat, Morgane Mounier, Ingrid Lafont, Frédéric Dos Santos, Aurélie Vidal, Marc Maynadié, Sylvie Hermouet   +8 more
doaj   +1 more source

Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study [PDF]

, 2019
Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with ...
Accurso V., Casimiro P., Contrino A. D., Di Piazza F., Perez A., Raso S., Russo A., Santoro M., Siragusa S.   +8 more
core   +1 more source

Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia

Haematologica, 2013
Subclones homozygous for JAK2V617F are more common and larger in patients with polycythemia vera compared to essential thrombocythemia, but their role in determining phenotype remains unclear.
Anna L. Godfrey, Edwin Chen, Francesca Pagano, Yvonne Silber, Peter J. Campbell, Anthony R. Green   +5 more
doaj   +1 more source

A case of CALR mutation in JAK2-negative patient with polycythemia

Онкогематология, 2022
JAK2 mutations can be associated with any phenotypic form of chronic myeloproliferative neoplasia, while MPL and CALR mutations occur, as a rule, in cases of essential thrombocythemia and primary myelofibrosis and they are not observed in polycythemia ...
T. N. Subbotina, I. E. Maslyukova, D. V. Kurochkin, M. A. Mikhalev, M. G. Osadchaya, V. A. Khorzhevskiy, T. A. Garkusha, E. A. Dunaeva, K. O. Mironov   +8 more
doaj   +1 more source

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms [PDF]

, 2018
We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs.
Arellano-Rodrigo, Eduardo, Barbui, Tiziano, Beggiato, Eloise, Bellini, Marta, Bertozzi, Irene, Betti, Silvia, Bonifacio, Massimiliano, Cacciola, Emma, Cacciola, Rossella, Carli, Giuseppe, Carobbio, Alessandra, Cattaneo, Daniele, Cazzola, Mario, Censori, Bruno, Cervantes, Francisco, Cortelezzi, Agostino, De Stefano, Valerio, Di Lazzaro, Vincenzo, Elli, Elena Maria, Ellis, Martin H., Finazzi, Guido, Finazzi, Maria Chiara, Gaidano, Gianluca, Gomez, Montse, Griesshammer, Martin, Guglielmelli, Paola, Hernandez-Boluda, Juan-Carlos, Iurlo, Alessandra, Loscocco, Giuseppe Gaetano, Lunghi, Francesca, Miroslava, Palova, Musolino, Caterina, Palandri, Francesca, Randi, Maria Luigia, Rapezzi, Davide, Rossi, Elena, Rumi, Elisa, Sadjadian, Parvis, Scaffidi, Luigi, Tieghi, Alessia, Vannucchi, Alessandro M., Vianelli, Nicola   +41 more
core   +5 more sources

All we know about polycythemia vera: literature review and own experience

Онкогематология, 2015
The literature review and own long-term polycythemia vera diagnosis and treatment experience are presented in this article. The results of newest advances in pathogenesis description, modern diagnostic techniques and treatment modalities in polycythemia ...
K. M. Abdulkadyrov, V. A. Shuvaev, I. S. Martynkevich   +2 more
doaj   +1 more source

Hereditary hemochromatosis and JAK2‐positive polycythemia vera

Clinical Case Reports, 2021
A 59‐year‐old man was diagnosed with JAK2‐positive polycythemia vera. Subsequently, further laboratory testing revealed elevated ferritin and iron saturation.
Ahmed Radwan, Ibraheem Othman
doaj   +1 more source

Double Thrombosis- Interesting Case of Polycythemia Vera [PDF]

Journal of Clinical and Diagnostic Research, 2020
Polycythemia vera is a myeloproliferative disorder which has a varied manifestation, one of it being venous thrombosis and arterial thrombosis which significantly contributes to the mortality and morbidity.
Subashini Subramanian, Siva Ranganathan Green   +1 more
doaj   +1 more source

Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis.

Blood Advances, 2020
Ruxolitinib is a recommended second-line treatment for the prevention of thrombosis in patients with polycythemia vera who become resistant or intolerant to hydroxyurea; however, evidence regarding its efficacy in terms of thrombosis reduction is ...
A. Masciulli, A. Ferrari, A. Carobbio, A. Ghirardi, T. Barbui   +4 more
semanticscholar   +1 more source